Comparative Pharmacology
Head-to-head clinical analysis: BENAZEPRIL HYDROCHLORIDE versus CAPOTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENAZEPRIL HYDROCHLORIDE versus CAPOTEN.
BENAZEPRIL HYDROCHLORIDE vs CAPOTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benazepril is a prodrug that is hydrolyzed to benazeprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE). This prevents conversion of angiotensin I to angiotensin II, resulting in decreased vasoconstriction, reduced aldosterone secretion, and lower blood pressure.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and increased plasma renin activity.
Initial: 10 mg orally once daily. Titrate to 20-40 mg daily (as single dose or two divided doses). Maximum: 80 mg/day. Route: Oral.
50 mg orally three times daily initially; maintenance 50-100 mg three times daily; maximum 450 mg/day.
None Documented
None Documented
Benazeprilat terminal elimination half-life is approximately 10-11 hours in patients with normal renal function; clinically, steady-state is reached in 2-3 days. Half-life is prolonged in renal impairment (up to 22 hours in moderate to severe impairment), necessitating dose adjustment.
Terminal elimination half-life is approximately 1.9 hours in healthy subjects, but prolonged in heart failure (up to 3-4 hours) and renal impairment (up to 5-10 hours).
Primarily renal (80-90% of absorbed dose excreted in urine, with approximately 20-30% as benazeprilat and the rest as inactive metabolites); biliary/fecal elimination accounts for the remainder (10-20%).
Primarily renal (approximately 60-75% as unchanged drug and metabolites) and biliary/fecal (approximately 20%).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor